{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:23Z","timestamp":1786985243904,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-LAB6-0001"],"award-info":[{"award-number":["ANR-14-LAB6-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007805","name":"College de France Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.biopha.2021.111682","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T20:40:05Z","timestamp":1621370405000},"page":"111682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats"],"prefix":"10.1016","volume":"140","author":[{"given":"Yannick","family":"Marc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Hmazzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"De Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Balavoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Llorens-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111682_bib1","series-title":"Manual of Hypertension of the European Society of Hypertension","author":"Mancia","year":"2019"},{"key":"10.1016\/j.biopha.2021.111682_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.biopha.2021.111682_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11906-019-1011-2","article-title":"The renin-angiotensin system in the central nervous system and its role in blood pressure regulation","volume":"22","author":"Nakagawa","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.biopha.2021.111682_bib4","doi-asserted-by":"crossref","first-page":"11968","DOI":"10.1073\/pnas.93.21.11968","article-title":"Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release","volume":"93","author":"Zini","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2021.111682_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.119.12675","article-title":"Evolution of a new class of antihypertensive drugs: targeting the brain renin-angiotensin system","volume":"75","author":"Llorens-Cortes","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2021.111682_bib6","doi-asserted-by":"crossref","first-page":"13415","DOI":"10.1073\/pnas.96.23.13415","article-title":"Aminopeptidase A inhibitors as potential central antihypertensive agents","volume":"96","author":"Reaux","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2021.111682_bib7","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2021.111682_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2021.111682_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2021.111682_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/HJH.0000000000001563","article-title":"Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats","volume":"36","author":"Marc","year":"2018","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2021.111682_bib11","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","volume":"37","author":"Azizi","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2021.111682_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of firibastat, a first-in-class brain aminopeptidase A inhibitor, in hypertensive overweight patients of multiple ethnic origins: a phase 2, open-label, multicenter, dose-titrating study","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2021.111682_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","article-title":"Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement","volume":"56","author":"Flack","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2021.111682_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/endo-90-2-422","article-title":"Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I","volume":"90","author":"Menard","year":"1972","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2021.111682_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2125.1981.tb01151.x","article-title":"Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects","volume":"11","author":"Brunner","year":"1981","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2021.111682_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3389\/fphar.2019.00815","article-title":"Mechanism of thiazide diuretic arterial pressure reduction: the search continues","volume":"10","author":"Rapoport","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2021.111682_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0021-5198(19)43215-0","article-title":"Antihypertensive action of a new angiotensin converting enzyme inhibitor, (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetr ahy dro-1,5-benzothiazepine-5-acetic acid (CV-5975), in various hypertensive models","volume":"47","author":"Inada","year":"1988","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111682_bib18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00004872-199611000-00012","article-title":"Effect of antihypertensive treatment and N omega-nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats","volume":"14","author":"Li","year":"1996","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2021.111682_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1440-1681.2011.05538.x","article-title":"Role of mineralocorticoid action in the brain in salt-sensitive hypertension","volume":"39","author":"Oki","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.biopha.2021.111682_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4103\/0974-8520.159034","article-title":"Evaluation of polyherbal formulation (SJT-HT-03) for antihypertensive activity in albino rats","volume":"35","author":"Ghelani","year":"2014","journal-title":"Ayu"},{"key":"10.1016\/j.biopha.2021.111682_bib21","first-page":"1019","article-title":"Studies on the mechanism of the synergistic antihypertensive activity of captopril and hydrochlorothiazide following acute administration in spontaneously hypertensive rats","volume":"4","author":"Chan","year":"1982","journal-title":"Clin. Exp. Hypertens. A"},{"key":"10.1016\/j.biopha.2021.111682_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0272-6386(85)80177-3","article-title":"Effects of enalapril alone, and in combination with hydrochlorothiazide, on renin-angiotensin-aldosterone, renal function, salt and water excretion, and body fluid composition","volume":"6","author":"Bauer","year":"1985","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2021.111682_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(81)90498-2","article-title":"Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats","volume":"76","author":"Sweet","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111682_bib24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cbi.2009.07.022","article-title":"The potential for interaction of hydrochlorothiazide with garlic in rats","volume":"181","author":"Asdaq","year":"2009","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.biopha.2021.111682_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.HYP.5.2.235","article-title":"Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients","volume":"5","author":"Holland","year":"1983","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2021.111682_bib26","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1097\/HJH.0000000000001106","article-title":"Copeptin is increased in resistant hypertension","volume":"34","author":"Mendes","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2021.111682_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjp.0702149","article-title":"Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin","volume":"125","author":"Stam","year":"1998","journal-title":"Br. J. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221004649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221004649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:37:10Z","timestamp":1778693830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221004649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":27,"alternative-id":["S0753332221004649"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111682","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111682"}}